Background: Tumor cell senescence is a common outcome of anticancer therapy. Here we
investigated how therapy-induced senescence (TIS) affects tumor-infiltrating leukocytes …

The potential of immune checkpoint inhibitors (ICI) may be limited in situations where
immune cell fitness is impaired. Here, we show that the efficacy of cancer immunotherapies …

Senescence, a cell-autonomous tumour suppressor mechanism, also has pro-tumorigenic
effects on neighbouring pre-malignant cells through the senescence-associated secretory …

Cellular senescence represents a double-edged sword in cancer and its therapy. On one
side, senescence-associated growth arrest and immunomodulatory properties exert potent …

Cellular senescence is a tumor suppressor response that has been observed both in vitro
and in vivo, and features of senescence have been documented in various human …

Cellular senescence is a stable proliferation arrest associated with an altered secretory
pathway (senescence-associated secretory phenotype). Cellular senescence is also a tumor …

Cellular senescence has emerged as a potent tumor suppressor mechanism in numerous
human neoplasias. Senescent cells secrete a distinct set of factors, collectively termed the …

Immunosenescence is a process of immune dysfunction that occurs with age and includes
remodeling of lymphoid organs, leading to changes in the immune function of the elderly …

Cellular senescence permanently restricts the replicative capacity of cells in response to
various stress signals, including aberrant activation of oncogenes. The presence of …

Background Immunosenescence, the age-related decline of immunity, affects the immune
responses of melanoma patients. Through immune responses, immune checkpoint …